LAUSANNE, Switzerland, Jan. 30,
2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:
ADCT), a commercial-stage global leader and pioneer in the field of
antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will
participate in a fireside chat at the Guggenheim SMID Cap Biotech
Conference on Thursday, February 6,
2025, at 2:00 p.m. ET.
A live webcast of the presentation will be available via the
Events & Presentations page in the IR section of the ADC
Therapeutics website. A replay of the webcast will be available for
approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT)
is a commercial-stage global leader and pioneer in the field of
antibody drug conjugates (ADCs). The Company is advancing its
proprietary ADC technology to transform the treatment paradigm for
patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in
London and New Jersey. For more information, please visit
the Company website at adctherapeutics.com and follow us on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
CONTACTS:
Investors
Marcy
Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-participate-in-the-guggenheim-smid-cap-biotech-conference-302363877.html
SOURCE ADC Therapeutics SA
